| answer text |
<p>The Government is committed to the safe and effective regulation of medicines in
the United Kingdom; ensuring patients and the public have fast access to new, innovative
medicines, including medicines for rare diseases.</p><p> </p><p>The agreement of an
implementation period will ensure that access to medicines continues, and patient
safety is maintained, in both the UK and European Union markets. Beyond that, the
Political Declaration sets out a plan for a free trade area for goods, underpinned
by deep regulatory co-operation, as well as a joint commitment to explore close cooperation
with the European Medicines Agency.</p><p> </p><p>The Government also continues to
prepare for the unlikely outcome that we leave the EU without any deal in March 2019.
The Department has been engaging with all pharmaceutical companies that supply the
United Kingdom with pharmacy or prescription-only medicines from, or via, the EU/European
Economic Area, on their contingency plans in the event of a no deal EU Exit.</p><p>
</p><p>Whatever the exit scenario, we will work to ensure that the UK will remain
a world leader for the treatment of rare diseases after the UK leaves the EU, that
UK patients are able to access the best and most innovative medicines including medicines
for rare diseases and that their safety is protected. The UK life sciences industry
has much to offer in creating, developing, trialing and commercialising medicines
that will benefit UK patients and strengthen the ability of the UK to compete internationally.</p>
|
|
